Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Warner Chilcott
ClinicalTrials.gov Identifier:
NCT00106028
First received: March 18, 2005
Last updated: April 15, 2013
Last verified: April 2013
Results First Received: April 15, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Osteogenesis Imperfecta
Interventions: Drug: risedronate sodium (Actonel)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
147 children > or = 4 and < 16 years of age with Osteogenesis Imperfecta (OI) enrolled at 20 North American and international study centers starting 16NOV2004. Patients weighing 10-30 kg received risedronate 2.5 mg or placebo daily and patients weighing more than 30 kg received risedronate 5 mg or placebo daily.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Daily placebo tablet, once a day for one year then for two years open label risedronate
Risedronate Daily risedronate tablet, once a day for one year then for two years open label risedronate once a day

Participant Flow:   Overall Study
    Placebo Daily     Risedronate Daily  
STARTED     49 [1]   94 [2]
Month 12 Completed/Started Open Label     49     87  
COMPLETED     43 [3]   82 [3]
NOT COMPLETED     6     12  
Adverse Event                 3                 2  
Protocol Violation                 1                 1  
Withdrawal by Subject                 2                 8  
Lost to Follow-up                 0                 1  
[1] ITT Population: Patients Randomized and Received at least 1 Dose of Study Drug
[2] ITT Population: Patients Randomized and Received at least 1 Dose of Study Drug
[3] Completed Month 36



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Daily placebo tablet, once a day for one year then for two years open label risedronate
Risedronate Daily risedronate tablet, once a day for one year then for two years open label risedronate once a day
Total Total of all reporting groups

Baseline Measures
    Placebo Daily     Risedronate Daily     Total  
Number of Participants  
[units: participants]
  49     94     143  
Age [1]
[units: participants]
     
<=18 years     49     94     143  
Between 18 and 65 years     0     0     0  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  8.6  ± 3.1     8.9  ± 3.4     8.825  ± 3.313  
Gender  
[units: participants]
     
Female     22     49     71  
Male     27     45     72  
Region of Enrollment  
[units: participants]
     
Australia     8     16     24  
Belgium     1     1     2  
Chile     4     9     13  
Czech Republic     1     4     5  
Finland     5     7     12  
Germany     5     8     13  
Hungary     2     2     4  
Italy     1     2     3  
Poland     5     9     14  
South Africa     0     1     1  
Spain     1     1     2  
United Kingdom     9     21     30  
United States     7     13     20  
[1] There were 147 children enrolled in the study (stated in the protocol). However, 4 children were randomized but did not receive a dose of the study drug. Therefore, only 143 received at least 1 dose of study drug.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

2.  Secondary:   Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

3.  Secondary:   Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

4.  Secondary:   Percent Change From Baseline in Total Body BMD at Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

5.  Secondary:   Percent Change From Baseline in Total Body BMD at Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

6.  Secondary:   Percent Change From Baseline in Total Body BMD at Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

7.  Secondary:   Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

8.  Secondary:   Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

9.  Secondary:   Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

10.  Secondary:   Percent Change From Baseline in Total Body BMC at Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

11.  Secondary:   Percent Change From Baseline in Total Body BMC at Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

12.  Secondary:   Percent Change From Baseline in Total Body BMC at Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

13.  Secondary:   Lumbar Spine Z-score - Percent Change From Baseline to Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

14.  Secondary:   Lumbar Spine Z-score - Percent Change From Baseline to Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

15.  Secondary:   Lumbar Spine Z-score - Percent Change From Baseline to Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

16.  Secondary:   Total Body Z-score- Percent Change From Baseline to Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

17.  Secondary:   Total Body Z-score- Percent Change From Baseline to Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

18.  Secondary:   Total Body Z-score- Percent Change From Baseline to Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

19.  Secondary:   Percent Change From Baseline in Lumbar Spine Bone Area at Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

20.  Secondary:   Percent Change From Baseline in Lumbar Spine Bone Area at Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

21.  Secondary:   Percent Change From Baseline in Lumbar Spine Bone Area at Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

22.  Secondary:   Percent Change From Baseline in Total Body Bone Area Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

23.  Secondary:   Percent Change From Baseline in Total Body Bone Area Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

24.  Secondary:   Percent Change From Baseline in Total Body Bone Area Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

25.  Secondary:   New Morphometric Vertebral Fracture at Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

26.  Secondary:   New Morphometric Vertebral Fracture at Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

27.  Secondary:   Categorization by Number of New Morphometric Vertebral Fracture at Month 12, ITT   [ Time Frame: Baseline and Month 12 ]

28.  Secondary:   Categorization by Number of New Morphometric Vertebral Fracture at Month 36, ITT   [ Time Frame: Baseline and Month 36 ]

29.  Secondary:   Incidence New Vertebral Fractures by SQ (Semi-Quantitative) Score, Patients Aged 4-9 Years, Month 12, ITT Population   [ Time Frame: Month 12 ]

30.  Secondary:   Incidence New Vertebral Fractures by SQ Score, Patients Aged 10-15 Years, Month 12, ITT Population   [ Time Frame: Month 12 ]

31.  Secondary:   Probability of Fracture in 12 Months (Kaplan-Meier Cumulative Incidence), ITT Population   [ Time Frame: Time to First Event (days) up to 12 Months ]

32.  Secondary:   Number of Clinical Fractures, Month 12, ITT Population   [ Time Frame: 12 Months ]

33.  Secondary:   Serum BAP - Percent Change From Baseline to Month 12, ITT Population   [ Time Frame: Baseline and 12 Months ]

34.  Secondary:   Serum BAP - Percent Change From Baseline to Month 24, ITT Population   [ Time Frame: Baseline and 24 Months ]

35.  Secondary:   Serum BAP - Percent Change From Baseline to Month 36, ITT Population   [ Time Frame: Baseline and 36 Months ]

36.  Secondary:   Urine NTX/Cr - Percent Change From Baseline at Month 12, ITT Population   [ Time Frame: Baseline and Endpoint / Month 12 ]

37.  Secondary:   Urine NTX/Cr - Percent Change From Baseline at Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

38.  Secondary:   Urine NTX/Cr - Percent Change From Baseline at Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

39.  Secondary:   Wong-Baker FACES Pain Rating Scale - Change From Baseline to Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

40.  Secondary:   Bone Age (Years), Change From Baseline to Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

41.  Secondary:   Bone Age (Years), Change From Baseline to Month 24, ITT Population   [ Time Frame: Baseline and Month 24 ]

42.  Secondary:   Bone Age (Years), Change From Baseline to Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]

43.  Secondary:   Annualized Growth Velocity - Change From Baseline to Month 12, ITT Population   [ Time Frame: Baseline and Month 12 ]

44.  Secondary:   Annualized Growth Velocity - Change From Baseline to Month 36, ITT Population   [ Time Frame: Baseline and Month 36 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The clinical meaningfulness of new fractures in the thoracic spine scored as Genant Grade I is unclear, thus the morphometric vertebral fracture data are evaluated further.  


Results Point of Contact:  
Name/Title: Grexan Wulff, Manager Regulatory Affairs
Organization: Warner Chilcott
phone: 973-442-3376
e-mail: gwulff@wcrx.com


No publications provided by Warner Chilcott

Publications automatically indexed to this study:

Responsible Party: Warner Chilcott
ClinicalTrials.gov Identifier: NCT00106028     History of Changes
Other Study ID Numbers: 2003100, HMR4003I/3001
Study First Received: March 18, 2005
Results First Received: April 15, 2009
Last Updated: April 15, 2013
Health Authority: United States: Food and Drug Administration